Allucent has appointed new therapeutic strategy leaders across key disease areas as it builds out its centres of expertise model, in a move that reflects growing demand for specialist support in complex drug development.

The company said the hires span oncology, neuroscience, cardiometabolic and immunology, alongside a new leadership role focused on advanced therapeutics such as rare diseases and cell and gene therapy.

The expansion comes as smaller biopharma companies increasingly work in complex and high-risk areas but rely on external partners to manage development, regulatory strategy and trial delivery.

Brant Nicks has joined as therapeutic strategy head for haematology and oncology,

bringing experience across early and late-stage development programmes. Roberta Anderson has been appointed therapeutic strategy head for neuroscience, with a background in central nervous system drug development and regulatory submissions.

Two internal appointments have also been confirmed. Mila Grieg will lead cardiometabolic and immunology and inflammation strategy, while Maria-Cruz Morillo will head advanced therapeutics, covering rare disease and cell and gene therapy programmes.

The company’s centres of expertise are designed to align scientific, regulatory and operational input within specific therapeutic areas. Allucent said this structure aims to improve study design, feasibility and execution across development stages.

Paula Brown Stafford, CEO of Allucent, said: “These appointments reflect the increasing complexity of drug development and the need for a more specialized, integrated approach. Small and mid-sized biopharma are advancing complex science but are often met with fragmented models that separate strategy from execution.”

She added: “Our ACEs are designed to change that, embedding scientific, regulatory, and operational leadership within each therapeutic area to streamline decision-making and accelerate execution.”

The update reflects a broader trend among contract research organisations to position themselves as strategic partners rather than service providers, particularly in areas such as oncology, neuroscience and rare diseases where trial design and regulatory pathways are more complex.

However, the announcement is largely a company-led positioning statement rather than independent industry news. It focuses on leadership hires and internal structure, with limited external validation of impact or client outcomes.

Allucent said its model integrates strategy and execution across all phases of development, with the aim of delivering faster and more predictable trial outcomes. The centres of expertise cover oncology, neuroscience, infectious diseases, cardiometabolic conditions and immunology, alongside advanced modalities such as cell and gene therapy.

The company did not disclose specific programmes, partnerships or performance metrics linked to the expanded leadership team.

As competition intensifies among CROs serving emerging biopharma, differentiation is increasingly based on therapeutic depth and the ability to support complex modalities. Allucent’s latest appointments suggest a continued shift towards disease-focused operating models.